Endothelial Dysfunction for Prognosis In Patients With preeClampSia
Recruiting · NCT06912477 · Observational (researchers observe without assigning treatment) · Lead sponsor: Heidelberg University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Preeclampsia is a pregnancy-specific hypertensive disorder and can progress rapidly to severe adverse outcomes affecting both the mother and the fetus. Endothelial and microcirculatory dysfunction mediate systemic preeclampsia-related organ dysfunctions. Changes in endothelial and vascular function in preeclampsia have been demonstrated through reduced flow-mediated vasodilation as a result of reduced availability of nitric oxide, which potentially persists up to several years postpartum. Hyperspectral imaging is a new innovative technology that allows to assess the peripheral microcirculation and perfusion non-invasively and contactless, but has never been evaluated in the context of preeclampsia before. This EPICS project (Endothelial dysfunction for Prognosis In patients with preeClampSia) is a prospective observational study and aims to investigate hyperspectral imaging as a new potential diagnostic and prognostic marker in preeclampsia.
Who can take part
Inclusion criteria
- singleton pregnancies
- Age ≥ 18 years
- Patient's ability to provide consent
- written informed consent
Exclusion criteria
- Lack of consent
- Language barrier
- Dark to very dark skin type
- Severe fetal chromosomal/genetic/structural anomalies
- Laboratory changes in LDH, creatinine, or platelets due to other causes (e.g., isolated thrombocytopenia, e.g., immune thrombocytopenia, carcinoma)
Where it is running
1 location listed.
- Heidelberg University Hospital, Department of Gynecology and Obstetrics - Heidelberg, Germany